

PRESS RELEASE



Piramal Pharma Solutions' Grangemouth, Scotland Site Wins Patient Awareness Council (PAC) Award for Excellence in Patient Centricity

- *The award recognizes the Grangemouth site's role in establishing a national Scottish Patient Awareness Council (SPAC).*
- *The SPAC initiative expands patient centricity efforts across Scotland, in partnership with the Scottish Government and other pharmaceutical companies.*
- *SPAC is designed to ensure that patient voices are a central component of developing healthcare solutions.*

Mumbai, India | November 12, 2024: Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA | BSE: 543635), announces that the Grangemouth Patient Awareness Council (PAC) is the recipient of this year's PAC Award for Excellence in Patient Centricity.

The prestigious award recognizes the Grangemouth PAC's crucial role in establishing the Scottish Patient Awareness Council (SPAC). This initiative aims to promote patient-centric experiences nationwide, underscoring the Grangemouth PAC's commitment to Piramal Pharma's core values and enhancing patient outcomes across Scotland.



SPAC emerged after representatives from the Grangemouth PAC connected with another CDMO with similar patient-focused principles. This collaboration highlighted a mutual aspiration to elevate the profile of life sciences in Scotland while celebrating the vital role they play in advancing patient care worldwide.

As a result, the Grangemouth PAC helped establish SPAC. This newly formed coalition unites life sciences companies across Scotland who share a common goal: to foster growth through patient empowerment and amplify the sector's voice for a healthier future.

SPAC reinforces the Grangemouth PAC's mission to champion a culture of patient centricity by prioritizing patients' needs and experiences in all aspects of life sciences development.



"We are incredibly proud of the Grangemouth PAC for spearheading a movement with significant potential within the life sciences sector," said Stu Needleman, Piramal's Chief Patient Centricity Officer. "By collaborating with like-minded organizations to empower patients, we can enhance healthcare outcomes and set a new benchmark for excellence in the industry. As Piramal Pharma looks to the future, we will continue advocating for initiatives that prioritize patient voices and drive significant change."

SPAC has created a robust platform for discussing best practices and sharing meaningful patient stories by collaborating with key stakeholders, including the Scottish Government, Scottish Enterprise, Edinburgh University, and others. The council serves as a vital platform for exchanging insights and experiences, ensuring that patient voices are central to developing effective healthcare solutions and instilling patient-centric values in the next generation of healthcare professionals.

Piramal Pharma Solutions remains dedicated to fostering a patient-centric culture across all its facilities, and the achievements of the Grangemouth PAC exemplify this commitment.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.

For more information visit: www.piramalpharmasolutions.com | [LinkedIn](#) | [Facebook](#) | [X](#)

About Piramal Pharma Ltd.

Piramal Pharma Limited (PPL, NSE:PPLPHARMA | BSE:543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter

consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics and vaccine segments. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.

For more information, visit: [Piramal Pharma](#) | [LinkedIn](#)

** Includes one facility via PPL's minority investment in Yapan Bio.*

For queries:

Gagan Borana

Investor Relations & Enterprise Risk Management

Gagan.Borana@piramal.com

Media contact:

Madiha Vahid

Madiha.Vahid@piramal.com